Awakn Life Sciences (TSE:AWKN) has released an update.
Awakn Life Sciences Corp. is collaborating with Eurofins Discovery and Graft Polymer to advance its pre-clinical program for developing new therapeutics aimed at treating mental health and addiction disorders, including Alcohol Use Disorder and PTSD. This partnership is a key move in Awakn’s strategy to bring innovative treatments to the market, potentially benefiting millions suffering from these conditions in North America and Europe.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
